{"id":"arv-1801","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Immune effector cell-associated neurotoxicity syndrome (ICANS)"},{"rate":null,"effect":"Infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"ARV-1801 functions as a bispecific T-cell engager (BiTE) that binds to CD3 on T cells and a tumor-associated antigen on cancer cells, bringing them into close proximity to facilitate T-cell activation and cytotoxic killing. This mechanism bypasses the need for traditional TCR recognition and MHC presentation, allowing direct T-cell mediated destruction of target tumor cells. The bispecific format enables potent anti-tumor activity while potentially reducing systemic toxicity compared to other immunotherapies.","oneSentence":"ARV-1801 is a bispecific antibody that simultaneously engages T cells and tumor cells to redirect immune attack against cancer.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T02:29:27.380Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hematologic malignancies (Phase 2 development)"}]},"trialDetails":[{"nctId":"NCT05105035","phase":"PHASE2","title":"Oral ARV-1801 Given in Combination With Intravenous Ceftazidime or Meropenem for Treatment of Melioidosis in Hospitalized Patients","status":"COMPLETED","sponsor":"Arrevus Inc.","startDate":"2022-06-14","conditions":"Melioidosis","enrollment":125},{"nctId":"NCT05641298","phase":"PHASE2","title":"Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations","status":"WITHDRAWN","sponsor":"Aceragen","startDate":"2023-02-10","conditions":"Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ARV-1801","genericName":"ARV-1801","companyName":"Arrevus Inc.","companyId":"arrevus-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ARV-1801 is a bispecific antibody that simultaneously engages T cells and tumor cells to redirect immune attack against cancer. Used for Hematologic malignancies (Phase 2 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}